CD22 Controls Germinal Center B Cell Receptor Signaling, Which Influences Plasma Cell and Memory B Cell Output

2021 ◽  
pp. ji2100132
Author(s):  
Sarah J. Meyer ◽  
Marie Steffensen ◽  
Andreas Acs ◽  
Thomas Weisenburger ◽  
Charlotte Wadewitz ◽  
...  
Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 3779-3779 ◽  
Author(s):  
Jennifer R. Chapman-Fredricks ◽  
Andrew J. Gentles ◽  
Daxing Zhu ◽  
Victoria Sujoy ◽  
Izidore S Lossos

Abstract Plasmablastic lymphoma (PBL) is currently recognized as a distinct sub-type of diffuse large B-cell lymphoma (DLBCL), but remains a poorly characterized B-cell malignancy. We conducted gene expression profiling of 15 PBL, 10 DLBCL, and 5 EOP (extraosseous isolated plasmacytoma). 864 genes were significantly over- or under-expressed (at<1% false discovery rate) uniquely in one of these diseases relative to the other two. Of these, 102 were highly expressed in PBL relative to DLBCL and EOP, while 166 showed low expression in PBL. This set of 268 genes defined a distinct transcriptional program operating in PBL. Among these were surface markers such as CD320, CD300A, and IL6 receptor, as well as the cytokine Oncostatin M, which was highly expressed in PBL but almost never expressed in DLBCL or EOP. CD320 plays a role in generation and proliferation of plasma cells in the germinal center in response to IL-10 stimulation, while the immunoglobulin superfamily member CD300 is variably expressed across the hematopoietic hierarchy. The apoptosis-inducer BAX (Bcl-2 associated X protein) was highly expressed in PBL, similar to reports in plasma cell neoplasms. In addition the CpG methyltransferase gene Dnmt3b showed high expression levels in PBL. By comparing malignancy-specific gene expression patterns to known biological pathways, we found that expression of components of the B-cell receptor signaling pathway (Cd79a, Cd79b, Blk, Lyn, Syk, Ptprc, Csk, Pik3cd, Swap70, and Rel) were repressed by 2-fold or more on average in PBL relative to DLBCL. We observed a similar pattern in EOP relative to DLBCL. In contrast, mitochondrial genes were more highly expressed in PBL than in DLBCL. Analysis against a large compendium of sets of transcription factor targets from motif and ChIP analyses identified that targets of MYB, a major transcriptional regulator of hematopoietic differentiation, were up-regulated in PBL; whereas targets of NFKB1 were repressed relative to DLBCL. Both PBL and EOP highly expressed genes that have previously been described as up-regulated in plasmacytomas. To further investigate the potential cell of origin of these malignancies, we compared genes expressed in PBL, DLBCL, and EOP to genes that are highly expressed in specific sub-types of B-cells. Genes highly expressed in plasma cells relative to other types of B-cells were highly expressed in PBL and EOP compared to DLBCL. Notably, this included the transcription factor XBP1 (X-box binding protein 1), which is a critical regulator of plasma cell differentiation. The plasma cell marker CD138 (syndecan-1, encoded by the Sdc1 gene) was also over-expressed in the PBL and EOP samples. We have validated the array data by reanalyzing expression of four candidate genes (Lyn, Syk, SPIB, and Swap70) by real time PCR. These four genes were highly expressed in DLBCL, but their expression was low in both in PBL and EOP. The observed overexpression of Swap70 in DLBCL as compared to PBL and EOP was subsequently validated by immunohistochemistry (IHC). Immunostaining for Swap70 was performed in all 30 cases used for array analysis and was negative in all cases of PBL (0/15 positive) and EOP (0/5 positive) but was diffusely positive in all but one of the DLBCLs (9/10 positive). Swap70 analysis by IHC was subsequently performed in 7 additional cases of DLBCL and was diffusely positive in all of these cases (7/7), thus suggesting that immunohistochemical analysis for Swap70 may be useful in differentiating PBL and EOP from DLBCL. Overall our results provide insight into the unique transcriptional programs distinguishing PBL from morphologic and clinical mimics DLBCL and EOP, as well as identify similarities between them. Most notably, we observed that B-cell receptor signaling pathway genes are significantly down-regulated in PBL and EOP compared to DLBCL. These findings corroborate the downregulation of surface immunoglobulin expression as seen in PBL and EOP and suggest a biologic similarity between these two neoplasms. Among normal B-cell sub-populations, PBL and EOP were most similar in their expression patterns to plasma cells and plasmablasts in that they expressed several well-known plasma cell markers. These findings additionally identify novel candidate genes that provide opportunities for further phenotypic and functional characterization of these neoplasms. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 583-583
Author(s):  
Delphine C.M. Rolland ◽  
Venkatesha Basrur ◽  
Kevin Conlon ◽  
Thomas Wolfe ◽  
Damian Fermin ◽  
...  

Abstract Abstract 583 Background: Reversible phosphorylation is a fundamental post-translational modification which regulates cellular functions by modulation of the activity of critical proteins in cellular signal transduction pathways. Deregulation of protein phosphorylation underlies the pathogenesis of many human diseases, especially cancers. Large scale phosphoproteomic analysis offer an opportunity to catalogue and understand changes in protein phosphorylation associated with cancers and thus provide new possibilities for discovering novel diagnostic biomarkers and new therapeutic targets. Although B-cell non-Hodgkin lymphomas (NHLs) represent the seventh most common cancer in western countries, the extent to which phosphoprotein deregulation may be involved in their pathogenesis is largely unknown. Here we report results of a label-free quantitative phosphoproteomics study of 3 B-cell NHL entities and investigate the contribution of one of the identified protein in the germinal center-derived NHL proliferation. Material and methods: Six milligrams of protein from 13 human B-NHL-derived cell lines (4 mantle cell lymphomas (MCL), 3 Burkitt lymphomas (BL) and 6 follicular lymphomas (FL)) digested by trypsin were subjected to phosphopeptide enrichment using metal oxide affinity chromatography (MOAC) and immunoprecipitation using a cocktail of 3 anti-phosphotyrosine antibodies. Phosphopeptides were subjected to liquid chromatography (LC) and MS/MS. Spectra were searched against the UniProtKB database using X!Tandem with k-score. Search results were then post-processed with PeptideProphet and ProteinProphet. All proteins at false discovery rate of 1% were considered for further analysis. Quantitation of identified peptides was based on spectral counts of phosphorylated peptides. Immunoprecipitation and western blot studies were performed to validate the differential phosphorylation of a subset of proteins. The functional consequences of perturbation of an outlier tyrosine phosphorylated protein (PAG1) were explored using shRNA-mediated depletion followed by both colony formation and proliferation assays with or without BCR stimulation by anti-IgM or lipopolysaccharide (LPS). Results: Quantitative phosphoproteomics revealed a total of 7326 serine/threonine phosphorylatided peptides and 392 tyrosine phosphorylated peptides corresponding to 420, 290 and 356 phosphorylated proteins in BL, FL and MCL, respectively. While a subset of phosphoproteins was identified across all lymphoma entities, hierarchical clustering analysis revealed distinctive signatures for all 3 NHL subtypes. Regarding proteins identified with phosphorylated tyrosine residues, BL and FL cell lines were characterized by phosphorylation of proteins implicated in active B-cell receptor signaling such as BTK, LYN, LCK and SYK whereas MCL cell lines were characterized by phosphorylation of proteins implicated in cell cycle control such as CDK1 and CDK2. Interestingly, we identified PAG1, a negative regulator of B-cell receptor signaling, as the most highly tyrosine phosphorylated protein in the germinal center derived cell lines (BL and FL) exclusively. Differential phosphorylation of several proteins was validated by immunoprecipitation and western blot studies. PAG1 silencing in BJAB (BL cell line) by a specific PAG1 shRNA resulted in an increased propensity for colony formation when compared to a scramble shRNA. PAG1 depletion also enhanced significantly the proliferation of BJAB 48h after BCR stimulation by either anti-IgM (3.9-fold increase versus 3-fold increase, p = 0.016) or LPS (4.2-fold increase versus 3-fold increase, p = 0.015). Conclusion: Our study reveals the utility of unbiased phosphoproteome interrogation of B-NHLs to characterize signaling networks that may provide insights into the pathogenetic mechanisms. We identify more than 500 phosphorylated proteins in each NHL entity revealing distinct protein phosphorylation signatures between MCL and germinal center derived lymphomas. Activation of the BCR signaling pathway is characteristic of and pathologically relevant in germinal center derived NHLs. The results of our study reveal novel phosphorylation sites and signatures that may be exploited as diagnostic biomarkers or therapeutic targets. Disclosures: No relevant conflicts of interest to declare.


2019 ◽  
Vol 291 (1) ◽  
pp. 190-213 ◽  
Author(s):  
Ryan M. Young ◽  
James D. Phelan ◽  
Wyndham H. Wilson ◽  
Louis M. Staudt

Sign in / Sign up

Export Citation Format

Share Document